by Sarcopenia is the age-related progressive loss of skeletal muscle mass and function. It leads to weakness, decreased mobility and physical disability in the elderly population. Sarcopenia treatment involves nutritional supplements, protein-rich diet, exercise program and medication. Nutritional supplements containing proteins, vitamins, minerals and amino acids are commonly prescribed to sarcopenic patients. Whey protein supplements are especially beneficial due to their high biological value and ability to stimulate muscle protein synthesis. Regular resistance and functional training helps in preservation and gain of muscle mass and strength. Certain medications such as creatine, testosterone and selective androgen receptor modulators (SARMs) are being researched for their anabolic effects on muscles.
The Global sarcopenia Treatment Market is estimated to be valued at US$ 3.47 Bn in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period 2024 to 2031.
Key Takeaways
Rapidly aging population globally is driving the demand for Sarcopenia Treatment Market Size . As per the UN’s World Population Ageing report 2017, the population aged 60 years and above is expected to reach 2.1 billion by 2050 from 962 million in 2017. The elderly are more susceptible to age-related loss of muscle mass and strength.
Key players operating in the Sarcopenia Treatment are Yokogawa, General Electric, Rockwell Automation, MAVERICK Technologies, Emerson, Siemens, Rudolph Technologies, Honeywell International, ABB, Schneider Electric, Aspen Technology.
Major pharmaceutical companies are focusing on geographic expansion into emerging markets to tap the vast untreated patient population suffering from sarcopenia. For instance, in 2021, Eli Lilly & Company launched its sarcopenia drug in several European countries.
Market Key Trends
Combination therapy involving nutritional supplements, exercise and medication is gaining traction for effective management of Sarcopenia Treatment Market Size. Researchers are investigating new anabolic drugs and therapeutic antibodies targeting specific pathways related to muscle growth for treatment of sarcopenia. Several drug candidates from companies including Astellas and Mereo BioPharma are in phase 2/3 clinical trials.
Porter’s Analysis
Threat of new entrants: New companies entering this market would require huge investment in R&D for developing new drugs , patents and approvals which makes entry difficult.
Bargaining power of buyers: As sarcopenia treatments are essential for patients, their bargaining power is low. The buyers have limited options currently in the market.
Bargaining power of suppliers: Major players dominate the supply market. Suppliers have significant influence over pricing as developing sarcopenia treatments require specialized expertise and infrastructure.
Threat of new substitutes: Currently no close substitutes are available for sarcopenia treatments. However, alternates like lifestyle changes, supplements, exercise and physical therapy provide limited relief.
Competitive rivalry: Major players competitively invest to develop innovative therapies, gain market share and maximize profits in this lucrative market.
Geographical Regions
North America accounts for the largest share of the sarcopenia treatment market currently, owing to increasing elderly population, healthcare expenditure and early disease diagnosis.
Asia Pacific region is poised to be the fastest growing market for sarcopenia treatments during the forecast period. This is attributed to rising geriatric population, growing economy, increasing healthcare access and presence of generic drug manufacturers in the region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
